JP2018516983A - ウイルス感染を処置するための組成物および方法 - Google Patents

ウイルス感染を処置するための組成物および方法 Download PDF

Info

Publication number
JP2018516983A
JP2018516983A JP2018513744A JP2018513744A JP2018516983A JP 2018516983 A JP2018516983 A JP 2018516983A JP 2018513744 A JP2018513744 A JP 2018513744A JP 2018513744 A JP2018513744 A JP 2018513744A JP 2018516983 A JP2018516983 A JP 2018516983A
Authority
JP
Japan
Prior art keywords
nuclease
nucleic acid
composition
genome
cmv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018513744A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018516983A5 (fr
Inventor
スティーブン アール． クエイク，
スティーブン アール． クエイク，
ジャンビン ワン，
ジャンビン ワン，
Original Assignee
アジェノビア コーポレーション
アジェノビア コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アジェノビア コーポレーション, アジェノビア コーポレーション filed Critical アジェノビア コーポレーション
Publication of JP2018516983A publication Critical patent/JP2018516983A/ja
Publication of JP2018516983A5 publication Critical patent/JP2018516983A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2018513744A 2015-05-29 2016-05-27 ウイルス感染を処置するための組成物および方法 Pending JP2018516983A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562168262P 2015-05-29 2015-05-29
US201562168259P 2015-05-29 2015-05-29
US62/168,259 2015-05-29
US62/168,262 2015-05-29
PCT/US2016/034606 WO2016196273A1 (fr) 2015-05-29 2016-05-27 Compositions et procédés pour traiter des infections virales

Publications (2)

Publication Number Publication Date
JP2018516983A true JP2018516983A (ja) 2018-06-28
JP2018516983A5 JP2018516983A5 (fr) 2019-06-27

Family

ID=57441664

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018513744A Pending JP2018516983A (ja) 2015-05-29 2016-05-27 ウイルス感染を処置するための組成物および方法

Country Status (4)

Country Link
EP (1) EP3331571A4 (fr)
JP (1) JP2018516983A (fr)
CA (1) CA3000189A1 (fr)
WO (1) WO2016196273A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3613852A3 (fr) 2011-07-22 2020-04-22 President and Fellows of Harvard College Évaluation et amélioration de la spécificité de clivage des nucléases
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US20150166985A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting von willebrand factor point mutations
CA2956224A1 (fr) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Proteines cas9 comprenant des inteines dependant de ligands
JP2018516984A (ja) * 2015-05-29 2018-06-28 アジェノビア コーポレーション 細胞を標的にしたｈｐｖ処置のための組成物および方法
US20190225955A1 (en) 2015-10-23 2019-07-25 President And Fellows Of Harvard College Evolved cas9 proteins for gene editing
WO2018027078A1 (fr) 2016-08-03 2018-02-08 President And Fellows Of Harard College Éditeurs de nucléobases d'adénosine et utilisations associées
AU2017308889B2 (en) 2016-08-09 2023-11-09 President And Fellows Of Harvard College Programmable Cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
WO2018119359A1 (fr) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Édition du gène récepteur ccr5 pour protéger contre l'infection par le vih
EP3592853A1 (fr) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression de la douleur par édition de gène
WO2018165629A1 (fr) 2017-03-10 2018-09-13 President And Fellows Of Harvard College Éditeur de base cytosine à guanine
IL269458B2 (en) 2017-03-23 2024-02-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
WO2018209320A1 (fr) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Arn guides incorporés par aptazyme pour une utilisation avec crispr-cas9 dans l'édition du génome et l'activation transcriptionnelle
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
EP3697906A1 (fr) 2017-10-16 2020-08-26 The Broad Institute, Inc. Utilisations d'éditeurs de bases adénosine
JP2021523745A (ja) 2018-05-16 2021-09-09 シンテゴ コーポレイション ガイドｒｎａ設計および使用のための方法およびシステム
MX2021011426A (es) 2019-03-19 2022-03-11 Broad Inst Inc Metodos y composiciones para editar secuencias de nucleótidos.
JP2023525304A (ja) 2020-05-08 2023-06-15 ザ ブロード インスティテュート，インコーポレーテッド 標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物
JP2023540427A (ja) * 2020-07-07 2023-09-25 オリエンジーン バイオテクノロジー リミテッド Ｈｓｖ－１遺伝子編集のためのガイドｒｎａおよびその方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150098954A1 (en) * 2013-10-08 2015-04-09 Elwha Llc Compositions and Methods Related to CRISPR Targeting

Also Published As

Publication number Publication date
WO2016196273A1 (fr) 2016-12-08
EP3331571A4 (fr) 2019-04-10
CA3000189A1 (fr) 2016-12-08
EP3331571A1 (fr) 2018-06-13

Similar Documents

Publication Publication Date Title
US10117911B2 (en) Compositions and methods to treat herpes simplex virus infections
JP2018516983A (ja) ウイルス感染を処置するための組成物および方法
US10066241B2 (en) Compositions and methods of delivering treatments for latent viral infections
US20160346362A1 (en) Methods and compositions for treating cytomegalovirus infections
JP2018516984A (ja) 細胞を標的にしたｈｐｖ処置のための組成物および方法
US20170088587A1 (en) Antiviral fusion proteins and genes
US20160348074A1 (en) Methods and compositions for treating cells for transplant
US20170247703A1 (en) Antiviral nuclease methods
US20170247690A1 (en) Oncoviral treatment with nuclease and chemotherapeutic

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190523

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200608

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201224